Tenaya Therapeutics, Inc. (TNYA)
NASDAQ: TNYA · Real-Time Price · USD
0.691
-0.009 (-1.29%)
At close: Apr 28, 2026, 4:00 PM EDT
0.695
+0.004 (0.58%)
After-hours: Apr 28, 2026, 7:51 PM EDT
Tenaya Therapeutics Employees
Tenaya Therapeutics had 70 employees as of December 31, 2025. The number of employees decreased by 27 or -27.84% compared to the previous year.
Employees
70
Change (1Y)
-27
Growth (1Y)
-27.84%
Revenue / Employee
n/a
Profits / Employee
-$1,294,243
Market Cap
149.95M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Fate Therapeutics | 161 |
| Molecular Partners AG | 134 |
| Alps Group | 93 |
| Immunic | 92 |
| Agenus | 81 |
| Spero Therapeutics | 25 |
| Black Diamond Therapeutics | 21 |
TNYA News
- 1 day ago - Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 - GlobeNewsWire
- 6 weeks ago - Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Tenaya Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy - GlobeNewsWire
- 7 weeks ago - Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Benzinga
- 7 weeks ago - Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - Reuters
- 7 weeks ago - Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - GlobeNewsWire
- 2 months ago - Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026 - GlobeNewsWire